Statins for primary prevention of cardiovascular disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Armitage, 2007, The safety of statins in clinical practice., Lancet, 370, 1781, 10.1016/S0140-6736(07)60716-8
Golomb, 2012, Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial., Arch Intern Med, 172, 1180, 10.1001/archinternmed.2012.2171
Mills, 2011, Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials., QJM, 104, 109, 10.1093/qjmed/hcq165
Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein., N Engl J Med, 359, 2195, 10.1056/NEJMoa0807646
Rajpathak, 2009, Statin therapy and risk of developing type 2 diabetes: a meta-analysis., Diabetes Care, 32, 1924, 10.2337/dc09-0738
Sattar, 2010, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials., Lancet, 375, 735, 10.1016/S0140-6736(09)61965-6
Preiss, 2011, Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis., JAMA, 305, 2556, 10.1001/jama.2011.860
2001, Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)., JAMA, 285, 2486, 10.1001/jama.285.19.2486
Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines., Circulation, 110, 227, 10.1161/01.CIR.0000133317.49796.0E
Wilson, 1998, Prediction of coronary heart disease using risk factor categories., Circulation, 97, 1837, 10.1161/01.CIR.97.18.1837
Conroy, 2003, Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project., Eur Heart J, 24, 987, 10.1016/S0195-668X(03)00114-3
Graham, 2007, European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)., Eur J Cardiovasc Prev Rehabil, 14, E1, 10.1097/01.hjr.0000277984.31558.c4
Catapano, 2011, ESCEAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)., Atherosclerosis, 217, 3, 10.1016/j.atherosclerosis.2011.06.028
Graham, 2007, European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)., Eur Heart J, 28, 2375, 10.1093/eurheartj/ehm316
Chen, 1991, Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations., BMJ, 303, 276, 10.1136/bmj.303.6797.276
Kearney, 2008, Cholesterol Treatment Trialists (CTT) CollaboratorsEfficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis., Lancet, 371, 117, 10.1016/S0140-6736(08)60104-X
Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins., Lancet, 366, 1267, 10.1016/S0140-6736(05)67394-1
Mihaylova, 2012, Cholesterol Treatment Trialists (CTT) CollaboratorsThe effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials., Lancet, 380, 581, 10.1016/S0140-6736(12)60367-5
Culver, 2012, Statin use and risk of diabetes mellitus in postmenopausal women in the womens health initiative., Arch Intern Med, 172, 144, 10.1001/archinternmed.2011.625
Ridker, 2009, Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)., Circ Cardiovasc Qual Outcomes, 2, 616, 10.1161/CIRCOUTCOMES.109.848473
Minder, 2012, Evidence-based use of statins for primary prevention of cardiovascular disease., Am J Med, 125, 440, 10.1016/j.amjmed.2011.11.013
2009, S. Preventive Services Task Force recommendation statement., Ann Intern Med, 150, 396, 10.7326/0003-4819-150-6-200903170-00008
Baigent, 2009, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials., Lancet, 373, 1849, 10.1016/S0140-6736(09)60503-1
Berger, 2006, Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials., JAMA, 295, 306, 10.1001/jama.295.3.306
Beishuizen, 2004, Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease., Diabetes Care, 27, 2887, 10.2337/diacare.27.12.2887
Bone, 2007, Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial., J Clin Endocrinol Metab, 92, 4671, 10.1210/jc.2006-1909
Peters, 2010, C-reactive protein lowering with rosuvastatin in the METEOR study., J Intern Med, 268, 155, 10.1111/j.1365-2796.2010.02230.x
Brugts, 2009, The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials., BMJ, 338, b2376, 10.1136/bmj.b2376
Ray, 2010, Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants., Arch Intern Med, 170, 1024, 10.1001/archinternmed.2010.182
Grundy, 2005, Diagnosis and management of the metabolic syndrome: an American Heart AssociationNational Heart, Lung, and Blood Institute Scientific Statement., Circulation, 112, 2735, 10.1161/CIRCULATIONAHA.105.169404
Ridker, 2012, Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial., Lancet, 380, 565, 10.1016/S0140-6736(12)61190-8
Waters, 2011, Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials., J Am Coll Cardiol, 57, 1535, 10.1016/j.jacc.2010.10.047
Waters, 2013, Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes., J Am Coll Cardiol, 61, 148, 10.1016/j.jacc.2012.09.042
Kashani, 2006, Risks associated with statin therapy: a systematic overview of randomized clinical trials., Circulation, 114, 2788, 10.1161/CIRCULATIONAHA.106.624890
Mills, 2008, Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients., J Am Coll Cardiol, 52, 1769, 10.1016/j.jacc.2008.08.039
Jukema, 2012, The controversies of statin therapy: weighing the evidence., J Am Coll Cardiol, 60, 875, 10.1016/j.jacc.2012.07.007
Ridker, 2010, Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5 to 10 and 10 to 20 10-year risk. Implications of the justification for use of statins in prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for intermediate risk., Circ Cardiovasc Qual Outcomes, 3, 447, 10.1161/CIRCOUTCOMES.110.938118
Lazar, 2011, Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era., Circulation, 124, 146, 10.1161/CIRCULATIONAHA.110.986349
Pletcher, 2009, Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering., Ann Intern Med, 150, 243, 10.7326/0003-4819-150-4-200902170-00005
Brugts, 2010, Statin prescription in men and women at cardiovascular risk: to whom and when Curr Opin C, ardiol, 25, 484